How Should Labels and Instructions for Use Be Localized for Medical Device Registration in India?

How Should Labels and Instructions for Use Be Localized for Medical Device Registration in India?

Published: 2026-07-15 13:23 | Updated: 2026-07-15 13:23

Direct answer: Before localizing labels and instructions for use (IFU) for medical device registration in India, a manufacturer should first confirm the target country, the product's risk class, the applicable regulatory pathway and the current state of its existing documentation. Only then should it assess the technical file, quality management system evidence, labels and IFU, local agent arrangements, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, incomplete documentation or ambiguous authorization arrangements do not unnecessarily extend the project timeline.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether documentation from NMPA, CE, FDA, ISO 13485 or other markets can be reused. Registration in a target market typically affects the technical file, authorized representative arrangements, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If a project moves forward only by asking which documents must be submitted, corrections or rework commonly arise in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends planning this question within a unified GHWP member state and multi-country access strategy, using one reusable core technical file to support localization across markets rather than re-creating documentation country by country.

This article reviews the issues manufacturers should prioritize in real projects across international medical device registration, documentation preparation, compliance pathways and post-market maintenance. It is compiled from AIMEILI's regulatory practice library, the medical device international registration knowledge base and public regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the manufacturer's underlying product documentation.

Article Structure

• Key Takeaways
• Applicable Scenarios and Core Questions
• Regulatory Decision Logic
• Documentation and Evidence
• Common Mistakes
• Manufacturer Preparation Checklist
• AIMEILI Perspective
• Frequently Asked Follow-Up Questions
• Further Reading
• Scope and Applicability

Key Takeaways

When addressing how labels and IFU should be localized for medical device registration in India, manufacturers should first confirm the target country, product risk class, applicable regulatory pathway and existing documentation base, and then assess technical documentation, quality management system requirements, labels and IFU, local agent arrangements, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission to avoid extended project timelines caused by unclear classification, documentation or authorization arrangements.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether documentation from NMPA, CE, FDA, ISO 13485 or other markets can be reused. Target market registration usually affects the technical file, authorized representative arrangements, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If a project is driven only by the question of which documents to submit, corrections or rework are likely to arise in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends planning this question within a GHWP member state and multi-country access strategy, using one reusable core technical file to support localization in different markets rather than re-creating documentation for each country on an ad hoc basis.

Applicable Scenarios and Core Questions

Manufacturers searching for guidance on how to localize labels and IFU for medical device registration in India are usually not looking for a conceptual explanation. They need to determine whether their existing documentation can support a submission in the target market, whether a local agent or authorized representative is required, why timelines become extended, and which issues may affect the market launch plan. This question typically involves product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibilities at the same time.

If a manufacturer plans to enter several GHWP member states or markets in Southeast Asia, the Middle East or Latin America simultaneously, answering the process for a single country is not sufficient. A more valuable approach is to first build reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labels and IFU, and then localize them in line with each country's regulatory requirements.

Regulatory Decision Logic

Manufacturers should first confirm the product's intended use, mechanism of action, use scenario, method and duration of body contact, whether it is sterile, whether it is active, and whether it incorporates software or IVD characteristics. Only then can the risk class and submission pathway be determined. Once the pathway assessment is incorrect, subsequent translation, notarization, authorization, testing and supplementary documentation will all move in the wrong direction.

For a target market project, it is also necessary to confirm the applicant entity and the boundaries of local responsibility: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are only addressed vaguely in commercial contracts, market control can easily be affected at a later stage.

Documentation and Evidence

Common documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or other applicable quality system evidence, technical file, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labels and IFU, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. IFU claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and information in the registration application form must all support one another. What regulators examine is whether the product is safe, effective and traceable for its intended use, not whether the manufacturer has uploaded a large number of files.

Common Mistakes

The most common problem is treating registration as a simple document submission exercise without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting translated NMPA documentation directly without restructuring the evidence according to the target market pathway.
• Listing too many models and specifications while test reports, clinical evidence or labels do not cover them adequately.
• Selecting a local agent purely on the basis of a sales relationship, without defining regulatory responsibilities, certificate control and post-market maintenance obligations.
• Claims in labels, IFU, promotional materials and registration documentation are inconsistent, leading to corrections or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, so that each country requires separate preparation and both cost and timelines are magnified.

Manufacturer Preparation Checklist

Before starting a project, manufacturers are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation and English-language IFU.
• Confirm the responsibilities, fees, certificate control and exit mechanisms of the local agent or authorized representative.
• Establish a target country gap assessment table that identifies what must be re-tested, translated, notarized or supported by additional declarations.

AIMEILI Perspective

AIMEILI recommends that manufacturers not view target market registration as a one-off document submission, but manage it as an overseas market access program. For manufacturers preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to national requirements is generally faster, more stable and better for subsequent changes and renewals than filling documentation gaps country by country.

From a project management perspective, three matters deserve early control: first, product classification and pathway assessment; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, a project may still experience repeated rounds of correction, agent communication and post-market maintenance issues even when the documentation appears extensive.

Frequently Asked Follow-Up Questions

Can domestic documentation be used directly for target market registration?

Domestic documentation can generally serve as a basis, but it usually cannot be submitted as is. Manufacturers need to adjust the documentation structure, language, labels, authorization documents and evidence chain in line with local regulatory requirements.

When is the best time to start a gap assessment?

A gap assessment should ideally be started immediately after the target market and product list are confirmed. The earlier it is completed, the easier it is to arrange re-testing, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

A local agent is typically involved in registration communication, changes, renewals and post-market event handling. Unclear responsibilities affect certificate control and the stability of the market afterwards.

Project Execution Recommendations

When executing this type of registration project, manufacturers should establish a project register that manages the product list, model specifications, registration pathway, documentation owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This makes documentation gaps visible in good time and helps management judge whether the project will affect the market launch plan.

For manufacturers with existing registrations in several countries, an evidence reuse matrix should also be established, specifying which documentation can serve as core evidence and which must be reissued or supplemented according to national requirements. Labels and IFU, clinical evaluation, risk management, performance verification and quality system certificates in particular must be kept version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway assessment.
• Establish a documentation gap assessment table.
• Define local agent responsibilities and certificate control.
• Track translation, notarization, testing and correction status.
• Assign post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope of an ISO 13485 certificate does not match the products being registered, or if the manufacturing address, model specifications or IFU version are inconsistent with test reports, additional clarification may be requested even when a large volume of documentation has been prepared.

Before submission, manufacturers should establish an evidence consistency checklist that maps the product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labels and IFU version, and quality system certificates item by item. This step appears basic, but it can significantly reduce the probability of corrections, especially for projects submitted simultaneously in multiple GHWP member states or for multiple product families.

Localization Adaptation and Agent Responsibilities

Target market registration projects usually involve arrangements for a local agent, authorized representative, importer or registration holder. Manufacturers need to confirm in advance whether the local partner is responsible only for submitting documentation, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and the stability of the market afterwards.

Labels, IFU and authorization documents also cannot simply be translated. Manufacturers should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For manufacturers that already hold CE, FDA, NMPA or other market documentation, the focus of localization is converting reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documentation.

Post-Market Maintenance and Long-Term Planning

Completion of registration does not mean compliance work has ended. Manufacturers must maintain certificate validity periods, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and records of regulatory updates. Many manufacturers invest substantial effort in obtaining the certificate but neglect post-market maintenance, which can later lead to a disconnect between the certificate and market sales when the manufacturing address changes, models are expanded, the IFU is updated or the agent is replaced.

AIMEILI recommends managing this question as part of an annual international registration plan: first establish target market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, corrections, post-market maintenance and renewal milestones. The value of this approach is not only greater efficiency in a single country, but also the development of a repeatable overseas compliance capability that reduces the cost of starting documentation preparation from scratch each time a new market is entered.

Further Reading

• Previous: How Should Technical Documentation Be Organized for Medical Device Registration in India?
• Next: How Should Clinical Evaluation Documentation Be Prepared for Medical Device Registration in India?
• How Should a Local Agent Be Selected for Medical Device Registration in Brazil?
• How Are Authorized Representative Responsibilities Defined for Medical Device Registration in Brazil?
• Why Do Registration Timelines Become Extended for Medical Device Registration in Brazil?
• What Are the Common Reasons for Documentation Corrections in Medical Device Registration in Brazil?
• How Is Post-Market Surveillance Conducted for Medical Device Registration in Brazil?
• When Must a Registration Change Be Filed for Medical Device Registration in Brazil?
• Return to the FAQ Center | News and Insights | Contact AIMEILI

Content Review and Scope of Applicability

Content author: AIMEILI Regulatory Editorial Team
Professional review: AIMEILI Medical Device International Registration Project Team
Sourcing principles: Priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only as supporting references.
Scope of applicability: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, test conclusions or legal advice.